SUMMARY: Predictors of bone mineral density (BMD) loss are additional tools in the management of osteoporosis in premenopausal women with systemic lupus erythematosus (SLE). This study provides original evidence that N-terminal propeptide of type 1 collagen (P1NP), the most specific bone formation marker, is a predictor of BMD loss in this group of women. INTRODUCTION: SLE is associated with a high risk of low bone mass/fractures but this risk is still controversial in premenopausal women. Our aim was to determine the 1 year incidence of BMD loss in premenopausal SLE women and the value of bone turnover markers as predictors of this complication. METHODS: This study enrolled a convenience sample of 63 premenopausal SLE patients. BMD was evaluated by dual X-ray absorptiometry at lumbar spine and hip at baseline and after 12 months. BMD changes above the least significant change were considered significant. Serum levels of P1NP and CTX (electrochemiluminescence), OPG, and RANKL (ELISA) were determined at baseline. RESULTS: Mean age was 31.1±6.8 years, and disease duration was 5.25±3.8 years. 36.5 % of patients presented BMD loss and 17.5 % BMD gain at lumbar spine and/or hip. Patients were divided in three groups: BMD loss (BL), no BMD change (NC), and BMD gain (BG). Patients with BL and NC received similar cumulative/mean/maximum glucocorticoid doses during the study, but patients with BG received lower doses (p<0.05). Baseline P1NP levels were different in the groups (BL: 36.95±23.37 vs. NC: 54.63±30.82 vs. BG: 84.09±43.85 ng/mL; p=0.031 BL vs. NC, p<0.001 BL vs. BG, and p=0.039 NC vs. BG). There was no difference in CTX, OPG, or RANKL levels. After multivariate analysis, P1NP remained as an independent risk factor for BMD loss (p<0.03). CONCLUSIONS: This study provides original evidence that lower levels of P1NP, the most specific bone formation marker, are predictive of BMD loss over 12 months in premenopausal SLE patients.
SUMMARY: Predictors of bone mineral density (BMD) loss are additional tools in the management of osteoporosis in premenopausal women with systemic lupus erythematosus (SLE). This study provides original evidence that N-terminal propeptide of type 1 collagen (P1NP), the most specific bone formation marker, is a predictor of BMD loss in this group of women. INTRODUCTION:SLE is associated with a high risk of low bone mass/fractures but this risk is still controversial in premenopausal women. Our aim was to determine the 1 year incidence of BMD loss in premenopausal SLEwomen and the value of bone turnover markers as predictors of this complication. METHODS: This study enrolled a convenience sample of 63 premenopausal SLEpatients. BMD was evaluated by dual X-ray absorptiometry at lumbar spine and hip at baseline and after 12 months. BMD changes above the least significant change were considered significant. Serum levels of P1NP and CTX (electrochemiluminescence), OPG, and RANKL (ELISA) were determined at baseline. RESULTS: Mean age was 31.1±6.8 years, and disease duration was 5.25±3.8 years. 36.5 % of patients presented BMD loss and 17.5 % BMD gain at lumbar spine and/or hip. Patients were divided in three groups: BMD loss (BL), no BMD change (NC), and BMD gain (BG). Patients with BL and NC received similar cumulative/mean/maximum glucocorticoid doses during the study, but patients with BG received lower doses (p<0.05). Baseline P1NP levels were different in the groups (BL: 36.95±23.37 vs. NC: 54.63±30.82 vs. BG: 84.09±43.85 ng/mL; p=0.031 BL vs. NC, p<0.001 BL vs. BG, and p=0.039 NC vs. BG). There was no difference in CTX, OPG, or RANKL levels. After multivariate analysis, P1NP remained as an independent risk factor for BMD loss (p<0.03). CONCLUSIONS: This study provides original evidence that lower levels of P1NP, the most specific bone formation marker, are predictive of BMD loss over 12 months in premenopausal SLEpatients.
Authors: D Jardinet; C Lefèbvre; G Depresseux; M Lambert; J P Devogelaer; F A Houssiau Journal: Rheumatology (Oxford) Date: 2000-04 Impact factor: 7.580
Authors: Maria Isabel Dutra Souto; Alycia Coelho; Carina Guo; Laura Maria C Mendonça; Maria Fernanda M C Pinheiro; Jose Angelo S Papi; Maria Lucia F Farias Journal: J Clin Densitom Date: 2012-02-09 Impact factor: 2.617
Authors: Sanford Baim; Charles R Wilson; E Michael Lewiecki; Marjorie M Luckey; Robert W Downs; Brian C Lentle Journal: J Clin Densitom Date: 2005 Impact factor: 2.963
Authors: Sandra C Fuchs; Sylvia M Guimarães; Cristine Sortica; Fernanda Wainberg; Karine O Dias; Mariana Ughini; José Augusto S Castro; Flavio D Fuchs Journal: BMC Public Health Date: 2002-01-16 Impact factor: 3.295
Authors: Rosa Maria Rodrigues Pereira; Jozélio Freire de Carvalho; Ana Patrícia Paula; Cristiano Zerbini; Diogo S Domiciano; Helenice Gonçalves; Jaime S Danowski; João F Marques Neto; Laura M C Mendonça; Mailze C Bezerra; Maria Teresa Terreri; Marta Imamura; Pedro Weingrill; Perola G Plapler; Sebastião Radominski; Tatiana Tourinho; Vera L Szejnfeld; Nathalia C Andrada Journal: Rev Bras Reumatol Date: 2012-08